SCHEMBL31100932

SCHEMBL31100932

O=C1CCC(Nc2ccc(CBr)nc2)C(=O)N1

nearest known ligand 0.59

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 20/20 0.59
CRBN Q96SW2 20/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31100604 0.87 DDB1 (0.66) DDB1CRBN
SCHEMBL31102040 0.87 DDB1 (0.59) DDB1CRBN
SCHEMBL23551580 0.87 DDB1 (0.59) DDB1CRBN
SCHEMBL24890785 0.87 DDB1 (0.59) DDB1CRBN
SCHEMBL31101661 0.87 DDB1 (0.59) DDB1CRBN
SCHEMBL31103065 0.82 DDB1 (0.67) DDB1CRBN
SCHEMBL31099665 0.80 DDB1 (0.51) DDB1CRBN
SCHEMBL23551217 0.80 DDB1 (0.63) DDB1CRBN
SCHEMBL24890782 0.80 DDB1 (0.68) DDB1CRBN
SCHEMBL21946764 0.80 DDB1 (0.68) DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4678638-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-01-14 EP claimed
WO-2024188209-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-09-19 WO claimed
EP-4678638-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-01-14 EP disclosed